Investors sold shares of Novavax Inc. (NASDAQ:NVAX) on strength during trading hours on Friday. $4.81 million flowed into the stock on the tick-up and $16.71 million flowed out of the stock on the tick-down, for a money net flow of $11.90 million out of the stock. Of all equities tracked, Novavax had the 0th highest net out-flow for the day. Novavax traded up $0.01 for the day and closed at $7.56

Several equities research analysts recently commented on NVAX shares. Chardan Capital started coverage on shares of Novavax in a research report on Monday, April 4th. They issued a “neutral” rating and a $5.75 price target for the company. Vetr upgraded shares of Novavax from a “buy” rating to a “strong-buy” rating and set a $8.35 price target for the company in a research report on Wednesday. Zacks Investment Research upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Friday, June 10th. Piper Jaffray Cos. restated an “overweight” rating and issued a $14.00 price target on shares of Novavax in a research report on Wednesday, June 29th. Finally, Wedbush restated an “outperform” rating and issued a $14.00 price target on shares of Novavax in a research report on Thursday, June 2nd. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Novavax has a consensus rating of “Buy” and a consensus price target of $12.21.

The firm’s 50-day moving average is $6.86 and its 200-day moving average is $5.76. The company’s market cap is $2.05 billion.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.02. During the same period last year, the company posted ($0.10) EPS. The firm had revenue of $4.20 million for the quarter, compared to the consensus estimate of $10.39 million. Novavax’s revenue for the quarter was down 57.6% compared to the same quarter last year. Equities research analysts expect that Novavax Inc. will post ($0.96) earnings per share for the current year.

In other news, Director Gary C. Evans sold 50,000 shares of Novavax stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $5.41, for a total transaction of $270,500.00. Following the completion of the sale, the director now owns 357,111 shares in the company, valued at approximately $1,931,970.51. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gary C. Evans sold 18,998 shares of Novavax stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $6.50, for a total transaction of $123,487.00. Following the sale, the director now owns 321,979 shares of the company’s stock, valued at approximately $2,092,863.50. The disclosure for this sale can be found here.

Several large investors have modified their holdings of NVAX. California State Teachers Retirement System boosted its stake in shares of Novavax by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 496,682 shares of the biopharmaceutical company’s stock valued at $4,167,000 after buying an additional 7,860 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Novavax by 10.4% in the fourth quarter. ProShare Advisors LLC now owns 266,138 shares of the biopharmaceutical company’s stock valued at $2,233,000 after buying an additional 25,114 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Novavax by 12.6% in the fourth quarter. Rhumbline Advisers now owns 271,881 shares of the biopharmaceutical company’s stock valued at $2,281,000 after buying an additional 30,395 shares in the last quarter. TD Asset Management Inc. boosted its stake in shares of Novavax by 7.5% in the fourth quarter. TD Asset Management Inc. now owns 576,800 shares of the biopharmaceutical company’s stock valued at $4,839,000 after buying an additional 40,000 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Novavax by 21.8% in the fourth quarter. American Century Companies Inc. now owns 354,286 shares of the biopharmaceutical company’s stock valued at $2,972,000 after buying an additional 63,306 shares in the last quarter.

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.